Skip to content

Histopathological Findings in Symptomatizing Patients After Supracervical Hysterectomy

Histopathological Findings in Symptomatizing Patients After Supracervical Hysterectomy

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04809727
Acronym
HSTH
Enrollment
88
Registered
2021-03-22
Start date
2017-12-01
Completion date
2021-01-31
Last updated
2021-04-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CIN, Cancer of Cervix, Cervicitis

Brief summary

Supracervical hysterectomy is widely common and had many complications either immediate or delayed. In these patients bleeding, infection, chronic pelvic pain are common. In these patients cervical biopsy was done and histopathological examinations were done to evaluate the pathology in these patients.

Detailed description

* Study design and settings: Cross sectional descriptive studies conducted from December 2017 till January 2021. * Patients: 80 patients with supracervical hysterectomy recruited at Tanta University Hospital, gynecology clinics will be recruited according inclusion and exclusion criteria. Inclusion criteria include all symptomatizing patients following supracervical hysterectomy, of any age, of any complaints. The exclusion criteria were patients with total hysterectomy, hysterectomies for malignant indications, and refusal to participate. * Methods: All patients' demographic data, history, indication of hysterectomy, duration since operation, postoperative complications and their main complaint. Intervention: under general anesthesia cervical biopsy (4 quadrants) were taken from all patients and was sent for histopathological examinations.

Interventions

4 quadrant biopsy

Sponsors

Tanta University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Intervention model description

All patients suffering after supracervical hysterectomy

Eligibility

Sex/Gender
FEMALE
Age
40 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* all symptomatizing patients following supracervical hysterectomy,

Exclusion criteria

* with total hysterectomy, * hysterectomies for malignant indications, * refusal to participate.

Design outcomes

Primary

MeasureTime frameDescription
Detection of cervical neoplasia or cancer incidence1 yearDetection of number of cases diagnosed with cervical Cervical intraepithelial neoplasia, or malignancy by histopathological examination
Detection of chronic cervicitis incidence1 yearDetection of number of cases diagnosed with inflammatory cells and other markers of inflammation

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026